Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on Top Healthcare Stocks: InflaRx (IFRX), Pfizer (PFE)

Tipranks - Tipranks - Tue Apr 14, 6:34AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on InflaRx (IFRX), Pfizer (PFE) and Alkermes (ALKS) with bullish sentiments.

Claim 30% Off TipRanks

InflaRx (IFRX)

Guggenheim analyst Yatin Suneja maintained a Buy rating on InflaRx today and set a price target of $14.00. The company’s shares closed last Friday at $1.00.

According to TipRanks.com, Suneja is a 5-star analyst with an average return of 29.1% and a 56.5% success rate. Suneja covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, MoonLake Immunotherapeutics, and Neumora Therapeutics, Inc. ;'>

Currently, the analyst consensus on InflaRx is a Strong Buy with an average price target of $7.33, implying a 604.8% upside from current levels. In a report issued on April 9, H.C. Wainwright also reiterated a Buy rating on the stock with a $6.00 price target.

See today’s best-performing stocks on TipRanks >>

Pfizer (PFE)

Guggenheim analyst Vamil Divan reiterated a Buy rating on Pfizer yesterday and set a price target of $36.00. The company’s shares closed last Friday at $26.92.

According to TipRanks.com, Divan is a 5-star analyst with an average return of 9.8% and a 56.3% success rate. Divan covers the Healthcare sector, focusing on stocks such as Unicycive Therapeutics, Eledon Pharmaceuticals, and Travere Therapeutics. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pfizer with a $29.02 average price target.

Alkermes (ALKS)

Piper Sandler analyst David Amsellem reiterated a Buy rating on Alkermes today and set a price target of $43.00. The company’s shares closed last Friday at $33.36.

According to TipRanks.com, Amsellem is a 4-star analyst with an average return of 6.5% and a 50.9% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Supernus Pharmaceuticals, Collegium Pharmaceutical, and Fennec Pharmaceuticals. ;'>

Alkermes has an analyst consensus of Strong Buy, with a price target consensus of $45.36, a 28.9% upside from current levels. In a report issued on April 4, Stifel Nicolaus also maintained a Buy rating on the stock with a $42.00 price target.

Read More on IFRX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).